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Abstract
Background: Alzheimer disease (AD) research has focussed mainly on the amyloid beta protein (Aβ). However,
many Aβ-and P3-type peptides derived from the amyloid precursor protein (APP) and peptides thought to derive
from Aβ catabolism share sequence homology. Additionally, conformations can change dependent on aggregation
state and solubility leading to significant uncertainty relating to interpretations of immunoreactivity with antibodies
raised against Aβ. We review evidence relating to the reactivities of commonly used antibodies including 6F3D,
6E10 and 4G8 and evaluate their reactivity profiles with respect to AD diagnosis and research.
Results: Antibody cross-reactivities between Aβ-type, P3-type and Aβ-catabolic peptides confound interpretations
of immunoreactivity. More than one antibody is required to adequately characterise Aβ. The relationships between
anti-Aβ immunoreactivity, neuropathology and proposed APP cleavages are unclear.
Conclusions: We find that the concept of Aβ lacks clarity as a specific entity. Anti-Aβ antibody cross-reactivities
lead to significant uncertainty in our understanding of the APP proteolytic system and its role in AD with profound
implications for current research and therapeutic strategies.
Keywords: Alzheimer disease, Amyloid beta protein, Amyloid precursor protein, Antibody, Cross reactivity,
Experimental design
Introduction
Research into the causes and progression pathways of
Alzheimer disease (AD) has focussed primarily on the
roles of the amyloid beta protein (Aβ) derived from the
amyloid precursor protein (APP) via sequential proteo-
lytic cleavages [1, 2]. In summary, there are two main
APP cleavage pathways, Fig. 1. The α-pathway involves
an initial α-cleavage to release the large extracellular sol-
uble sAPPα leaving the 83 amino acid (aa) residue
carboxy terminal fragment (CTF) in the membrane. This
is further processed by γ-secretase containing Presenilin
(PS) to release the variable length P3 peptide and the
APP intracellular domain (AICD). This pathway is
thought to be constitutive and α-cleavage precludes pro-
cessing by the β-secretase BACE1 as it cuts within the
Aβ sequence. In competition with α-cleavage and with
APP expression as rate limiting [3], β-cleavage releases
the large extracellular soluble sAPPβ leaving a 99 aa resi-
due CTF in the membrane that is further processed by
the shared sequential γ-secretase to release the variable
length Aβ and the AICD. The main fragments expressed
are the large sAPPα and sAPPβ domains, the smaller
variable length Aβ and P3 fragments and the AICD, all
sharing sequence homology to varying degrees with each
other and with full length APP. Additional APP cleav-
ages include β’-cleavage by BACE2 [4], δ- and η-cleavage
[5, 6] and cleavage by caspase [7]. BACE2 may also be
involved in catabolism of Aβ [8].
Evidence relating to Aβ from autosomal dominant
genetic mutations in the amyloid precursor protein
(APP) and presenilins (PS) in familial AD (FAD) [9, 10],
coupled with the neuropathological diagnostic value as-
sociated with the presence of deposits of Aβ in the brain
in both FAD and sporadic AD (SAD) [11, 12], has been
interpreted in the amyloid cascade hypothesis as show-
ing a causal role for Aβ in disease progression [13, 14]
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and has been updated to reflect the ratios of Aβ (1–42)/
Aβ (1–40) [14, 15] or oligomers [16, 17]. However, this
interpretation of the evidence relating to Aβ has not
been fully accepted and alternative interpretations
including the presenilin hypothesis [18, 19] and the APP
matrix approach [20, 21] have been put forward.
In addition to Aβ40 and Aβ42, the peptides at the
main focus of research, there are many soluble [22] and
insoluble Aβ-type peptides, including N-terminal ex-
tended peptides [23], that have yet to be fully described
and accounted for in theoretical and experimental
disease models. In addition to different sequences, Aβ-
type peptides can exist in a variety of aggregation states
including monomers, dimers, oligomers and fibrils.
Evidence that behaviour profiles differ between the vari-
ous Aβ-type sequences and aggregation states suggests
that some Aβ species, such as Aβ42 or oligomers, may
be more important in disease progression than others.
Evidence from population studies [24–26] suggests
that correspondence between clinical dementia status
and neuropathological diagnosis blind to clinical demen-
tia status in the older population where most dementia
occurs, do not correspond well. The relationships be-
tween Aβ, neuropathology and clinical dementia status
are not clear. In order to investigate these relationships
an understanding of the different presentations of Aβ
across the different sequence lengths, aggregation states
and neuropathological associations is required.
AD research has depended greatly on the use of anti-
bodies. Concerns regarding the interpretation and
reliability of antibodies relating to reproducibility of sci-
ence in general have been previously highlighted [27].
Antibodies have been raised against various Aβ epitopes
and these recognise slightly different pathological pro-
files [28–31]. Because Aβ-type peptides share sequence
homology and conformations to varying degrees, cross
reactivity can potentially confound interpretations of
immunoreactivity. Here we look at evidence relating to
the reactivities of the commonly used antibodies 6F3D,
6E10 and 4G8 immunoreactive with Aβ and ask how the
reactivity profiles of commonly used antibodies relate to
AD diagnosis and research.
Antibody reactivities with peptides from α-, β- and
γ- cleavages
The epitopes recognised by 6F3D, 6E10 and 4G8 to various
forms of Aβ, Fig. 2a and Table 1, are usually interpreted to
be sequence specific and relate to proteolytic fragments re-
leased following sequential β- and γ-cleavages.
6E10 recognises an epitope in the N-terminal region
of both Aβ40 and Aβ42. The 6E10 N-terminal epitope is
also recognised in Aβ (1-16/17), a fragment that could
reflect catabolism of Aβ [3, 32], or additional processing
of the C99 carboxy terminal membrane bound fragment
(CTF) following β-cleavage [33]. The fragment Aβ
(1-11/12) detected in soluble fractions [34] and
generated following catabolism of full length Aβ by
BACE2 [8] is predicted to react with 6E10, Fig. 2b,
but this has not been investigated.
Fig. 1 APP cleavage pathways. Green: sequential α- and γ- cleavages of the α- pathway, red: sequential β- and γ- cleavages of the β- pathway,
grey: alternative fragments from β’ cleavage or shared full length APP and AICD. Other cleavage pathways such as δ and η are not shown
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Antibody 6F3D recognises an N-terminal epitope
present in full length Aβ42, Aβ40 and is predicted to
react with Aβ (1-16/17) but unlike 6E10, not Aβ (1-11/
12). Neither 6F3D nor 6E10 are predicted to react with
P3-type peptides, equivalent to Aβ (16/17-40/42) derived
from sequential α- and γ- cleavages of APP [1] that lack
the amino acid sequence of the epitope. As such 6E10
and 6F3D represent initial β-cleavage but do not inform
on C-terminal variability due to carboxypeptidase activ-
ities of γ-cleavage [35]. This may be generally applicable
to other antibodies recognising N-terminal epitopes,
such as 6C6, which also recognise N-terminal epitopes
[34]. Interpretation could be further complicated by re-
activities with shorter N-terminal peptides derived from
full length Aβ by catabolism or additional processing of
membrane bound CTF and shorter C-terminal endings,
seen in conditioned media from cell culture [22].
Antibodies specific for C-terminals ending at aa Aβ40
or Aβ42 are traditionally interpreted as representing Aβ.
However, antibodies specific for Aβ40 MBC40 and Aβ42
MBC40 were noted to react with shorter N-truncated
Aβ peptides including P3 (40) and P3 (42) respectively
[29]. Antibodies reactive with either Aβ40 or Aβ42 are
also predicted to react with shorter peptides from Aβ ca-
tabolism, Fig. 2, though this will depend on whether the
exact epitope recognised is still present in the shorter
sequence. Characterisation of epitopes recognised by
antibodies in general is a widely held concern. While
studies using antibodies raised against Aβ40 or Aβ42
will monitor the specificity of C-terminal epitopes or
cross reactivity with full length APP [36], very few
account for N-terminal variation. Therefore we cannot
be certain that any antibody thought to represent Aβ40
or Aβ42 derived from sequential β- and γ- cleavages
actually represents full length rather than peptides from
other cleavages lacking the N-terminal epitopes. Immu-
noreactivity with the antibodies recognising fragments
ending in either aa40 or aa42 of Aβ should be
Fig. 2 Epitopes recognised by commonly used antibodies in various Aβ –type peptides. a fragments associated with the main α- and
β- cleavage pathways, b fragments associated with BACE2 catabolism. Note: Aβ can exist as monomers, dimers, oligomers and fibrils; epitopes
may be lost due to conformational change due to aggregation/solubility etc.; antibodies do not react with specific Aβ sequences in all
conditions; amino acids of epitopes for MBC40 (Aβ40) and MBC42 (Aβ42) not well described
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interpreted as representing fragments from γ-cleavage
regardless of initial α- or β- cleavages unless cross re-
activity checks prove otherwise.
Aβ- type, P3-type, Aβ’, equivalent to Aβ (11/12-4x) re-
leased following cleavage by BACE2 and γ-cleavage [4]
or following catabolism of the full length Aβ peptide [8],
and various fragments derived from catabolism share se-
quence homology, Fig. 2 and Table 1. In human kidney
293 cell culture medium, approximately 69% of peptides
released following γ- cleavage were found to be P3-type,
around 20% are Aβ-type and 11% are Aβ’-type [37] how-
ever, different expression systems may give different
ratios and these ratios may not reflect the levels of
expression in the human brain. Shorter fragments in
Fig. 2, including Aβ (11/12-19/20), Aβ (19/20-34), Aβ
(19/20-42), Aβ (19/20-40), Aβ (35–42) and Aβ (35–40)
are predicted from BACE2 catabolism of full length Aβ
[8]. These shorter Aβ-type peptide sequences have been
largely neglected in AD research and their expression
levels in human tissues remains to be fully described. No
study to date has systematically characterised all these
fragments in the human brain. Aβ (1-4x), P3 (17-4x),
Aβ’(11/12-x) and Aβ’(11/12-34) type peptides are pre-
dicted to react with the 4G8 antibody, reactive with an
epitope within aa 18–23. Therefore 4G8 detects prod-
ucts from γ-cleavage irrespective of the initial primary
cleavage but should not detect catabolic fragments
following degradation of full length Aβ (1-4x) missing
the intact epitope sequence. 4G8 also shares a conform-
ational epitope with other fibril forming proteins includ-
ing α-synuclein [38] that is sequence independent.
While these epitopes are assumed to be sequence
specific, this cannot be guaranteed. Aβ exists in many
aggregation states from monomers, dimers, oligomers
and fibrils. These conformation changes can potentially
lead to changes in the presentation of epitopes and nei-
ther 6E10 nor 4G8 were found to react with all samples
of Aβ when aggregated under various conditions [39].
Reactivity was found to change depending aggregation,
suggesting that epitopes can be revealed or hidden by
different conformations and at least two different aggre-
gated conformations may be present depending on spe-
cific conditions. This study shows that antibodies
reactive with Aβ-type peptides are both sequence and
conformation dependent [39]. 4G8 specifically was
found not to react with Aβ40 at higher molecular weight
oligomers and reacted with high molecular weight Aβ42
only when aggregated under conditions with agitation.
Therefore 4G8 immunoreactivity cannot be assumed to
visualise “total” Aβ.
The use of antibodies in diagnosis and research
AD diagnosis and research in the human brain depends
on the use of antibodies reactive with Aβ. It is essential
Table 1 Epitopes and cross reactivities of selected antibodies raised against Aβ
Antibody Epitope Cross Reactivity Ref
4G8 Raised against synthetic peptide Aβ17-24; epitope lies
within aa 18–23; recognises multiple forms of Aβ
Cross reacts with APP770 and P3; reacts with conformational
epitope of aggregated fibrils including α-synuclein
[29, 38, 39]
6E10 Raised against Aβ1-17; epitope lies within aa 4–9;
recognises Aβ with intact N-terminal epitope
Cross reacts with APP and Aβ (1–16); No reaction predicted
with P3
[3, 29]
6F3D Raised against synthetic peptide Aβ8-17; epitope lies
within aa 10–15; recognises Aβ with intact N-terminal
epitope
Predicted to react with Aβ (1–16); Does not react with P3 [29, 31]
MBC40 (Aβ40) Recognises C-terminal Aβ peptides ending at aa40;
epitope not well described
Cross reacts with N-terminal truncated peptides including P3 [29]
MBC42 (Aβ42) Recognises C-terminal Aβ peptides ending at aa42;
epitope not well described
Cross reacts with N-terminal truncated peptides including P3 [29]
BS85 Raised against Aβ (25–35); recognises Aβ38, Aβ39,
Aβ40, Aβ42 and Aβ43; epitope not well described
Cross reacts with N-terminal truncated peptides including P3 [28]
BC05 Raised against Aβ (35–43); recognises Aβ42 and
Aβ43; epitope not well described
Cross reacts with N-terminal truncated peptides including P3;
does not recognise Aβ40; used in commercial ELISA kits for the
detection of Aβ42
[28, 44]
BA27 Raised against Aβ (1–40) Recognises Aβ40; 100-1000x
more reactive with Aβ40 than Aβ42 and Aβ43; epitope
not well described
Cross reacts with N-terminal truncated peptides including P3;
used in commercial ELISA kits for the detection of Aβ40
[28]
AβN17 (Leu) Raised against P3 (40); recognises P3 (40) and synthetic
P3 (42) peptide; epitope not well described
Reactivity with insoluble, aggregated P3 (42) not confirmed [28, 42, 57]
3D6 Raised against Aβ with N-terminal aspartic acid; epitope
not well described
Does not cross react with sAPPs or full length APP; No reaction
predicted with P3; parent of Bapineuzumab; epitope not well
described
[53]
Raised against Aβ (13–28); epitope not well described Solanezumab [53]
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that results from studies across the world are compar-
able and attempts to standardise inter-laboratory com-
parisons of amyloid pathology [30, 40] have found that
immunohistochemical approaches are more reliable than
silver stain based techniques. Further, because 4G8
shows more Aβ immunoreactive pathology than either
6E10 or 6F3D, it has been recommended as the antibody
of choice for diagnostic work to visualise deposits of Aβ
[30], perhaps implying that increased immunoreactivity
represents increased sensitivity for Aβ. However, if we
consider the reactivity of 4G8 with fragments from the
wider APP proteolytic system, not all reactivity necessar-
ily represents Aβ. Thal et al. [29] stained sequential sec-
tions from a case with extensive Aβ pathology with
6E10, 6F3D, 4G8, MBC40 and MBC42 Table 1. They
found strong reactivity of plaques with MBC42 and 4G8
but little reactivity with MBC40 and 6F3D suggesting
that the majority of staining was due to N-truncated
peptides equivalent to P3 (Aβ17-42) [29]. However, this
interpretation of the staining patterns is not straightfor-
ward as loss of staining with 6F3D could also reflect a
change in aggregation state that hides the 6F3D epitope
especially for Aβ42 which may be more prone to aggre-
gation and insolubility or may be lost due to membrane
binding [41]. Therefore antibodies to N-terminal
epitopes of Aβ, such as 6F3D and 6E10 may not be
revealing all Aβ (1-4x).
Over 40 soluble Aβ-type peptides are biologically
present [22]. Interestingly, the peptide P3 (42), repre-
senting the peptide thought to be associated with neuro-
pathology of diffuse senile plaques [29] is not listed in
Table 2 in Wang et al 1996 [22] even though the use of
4G8 as a capture antibody is predicted to react with it.
This suggests that the more insoluble P3 (42) aggregated
in plaques could adopt a significantly different conform-
ation to P3 (40) found in the soluble compartment and
this requires clarification.
The results obtained by Thal et al. [29, 31] are com-
patible with those using different monoclonal antibodies,
BS85 reacting with multiple forms of Aβ, BC05 – react-
ing with Aβ42/3 and BA27- reacting with Aβ40 in a
different study that did not account for N-terminal vari-
ation [28]. This study found similar reactivity profiles for
BS85 and BC05, marking multiple cored and fleecy
amyloid senile plaques whereas BA27, reactive for C-
terminal Aβ40, detected cored senile plaques only. In a
follow-up study, Iwatsubo et al. [42] used an antibody
raised against the N-terminal of P3 to measure the de-
position of P3 and found little reactivity, suggesting that
P3 is not involved in neuropathological deposition. How-
ever as with Aβ42, this could reflect the different solu-
bilities and aggregation states of P3-type peptides where
P3 (40) is seen in the soluble pool of fragments whereas
P3 (42) is not [22]. It is important to note that synthetic
peptides of soluble P3 (40) were used to select the N-
terminal antibody AβN17 (Leu) in this study and al-
though reactivity was noted with P3 (42) in western blot
analysis, the aggregation of the synthetic P3 (42) peptide
was not considered. As with the reactivity of 6F3D with
Aβ40 discussed above, the contributions of aggregation
state of P3 (42) and consequent loss of epitope cannot
be dismissed. Indeed these staining patterns may indi-
cate that the epitopes contained in the N-terminal of P3
are solubility dependent and are lost in aggregated P3
(42), associated with diffuse amyloid deposition and
therefore no reactivity in diffuse plaques with antibodies
recognising P3 (40) or non-aggregated P3 (42) would be
expected. This interpretation is compatible with the
scant reactivity of MBC40 and BA27, showing no re-
activity for peptides ending with aa40 [29, 42]. Consider-
ation must be given to solubility and aggregation state
when interpreting antibody reactivities.
A few studies explicitly account for antibody cross re-
activities. Citron et al. [43] describe the reactivity of
R1280 as “a polyclonal antiserum raised against
synthetic Aβ1–40… and precipitates Aβ (4 kDa), p3
(3 kDa), and small amounts of APPS” and in another
paper [44] they explicitly describe the reactivities of the
monoclonal antibody 21 F12 as immunoprecipitating Aβ
(42) and P3 (42), the monoclonal antibody BCO5 detect-
ing Aβ (42) and P3 (42) and the polyclonal antibody C42
detecting Aβ (42) and P3 (42). Watson et al. [45] note
that both polyclonal R1280 and R1282 immunoprecipi-
tate soluble Aβ, P3 and related peptides. As already
discussed Thal et al. [29] explicitly describe the reactivity
of MBC40 with Aβ40 and P3 (40) and MBC42 with
Aβ42 and P3 (42). However, few more recent studies
explicitly account for antibody reactivity profiles with a
potential for cross reactivities to confound interpreta-
tions of immunoreactivity patterns.
Study designs using a capture antibody reactive with
epitopes within the first 16 amino acids of Aβ to select
only Aβ peptides resulting from β-cleavage as an initial
step e.g. Moore et al. [3, 46] leave any P3 type peptides
unrecorded and not accounted for. Where studies use a
capture antibody reactive with the N-terminal of Aβ, fur-
ther characterisation with antibodies detecting C-ter-
minal aa 40 or 42 can be interpreted as representing
Aβ40 or Aβ42 from β-cleavage. However, a study using
this approach to quantify Aβ40/42 in wet tissues then
investigated location using only antibodies reactive with
Aβ42 in formalin fixed, paraffin embedded tissues [34]
where results have been interpreted as showing both
quantity and location of Aβ42. However, this study de-
sign is potentially confounded by cross reactivity with P3
(42) in formalin fixed, paraffin embedded tissue that has
not been checked. Keeping experimental approaches
consistent both within and between studies is a
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challenge but one that requires urgent attention. Some
commercial ELISA kits use BA27 to detect Aβ40 and
BC05 to detect Aβ42, however, since both these anti-
bodies are known to also recognise P3 (40) and P3 (42)
respectively, we cannot be certain that any results
obtained are not confounded by P3. Antibody reactivity
profiles with potentially similar peptides from the APP
proteolytic system should always be checked.
How do we best interpret the available evidence
derived from antibody reactivities?
Interpretation of the reactivities of antibodies immuno-
reactive with Aβ-type peptides is not straightforward
and is compounded by the lack of systematic definitions
of Aβ-type peptides. On the one hand Aβ is often
discussed as a homogenous whole, where the different
sequence lengths and aggregation states are collapsed
under “Aβ” as an umbrella concept. Yet, because the
different fragments sequences and aggregation states
show discrete behaviours, this umbrella concept may not
be useful for more detailed research questions investigat-
ing the role (s) of Aβ in disease pathways. Should each
possible fragment derived from α-, β-, and γ- cleavages
and Aβ catabolism be experimentally controlled for in a
systematic approach? The different behaviours of the
Aβ-type and P3-type fragments depending on aggrega-
tion state suggest that this may be an important issue
that has yet to be fully incorporated in experimental
design. This is not straightforward as the contributions
of each possible sequence can potentially vary with
solubility and aggregation state, certainly increasing ex-
perimental costs as each fragment is controlled for.
Because 4G8 is increasingly recommended for diag-
nostic work [30], and because reactivity is interpreted as
Aβ (umbrella concept) it is probable that the contribu-
tions of P3 (42) to neuropathological classifications have
been hidden in current experimental designs and there-
fore neglected. However, not all laboratories use 4G8
and instead use 6E10 or 6F3D, specific for N-terminal
epitopes of Aβ that do not detect P3-type fragments.
These antibodies visualise qualitatively different aspects
of Aβ deposition, i.e. lacking contributions from P3-type
fragments [31] potentially confounding comparisons be-
tween studies from different laboratories using different
antibodies [29, 30]. If all laboratories were to use 4G8,
this would potentially confound how we understand the
deposition of specific Aβ-species as it detects a wide
range of fragments, not all necessarily Aβ. This con-
founding would also be relevant to the use of antibodies
reactive with The C-terminal residues from Aβ40 and
Aβ42, as N-terminal variation is not detected. The only
option to systematically detect specific peptides is to use
multiple antibodies reacting with the different epitopes
or use a capture antibody relevant to the experimental
design, such as 4G8 as in [22] or 6E10 as in [3, 22] and
then analyse any fragments further with for example,
mass spectroscopy. However, it must be born in mind
that a single antibody will not capture all possible Aβ-
or P3 type fragments in all aggregations states [39] and
this must be explicitly accounted for in any experimental
design. The different antigen retrieval methods [47], dif-
ferent profiles of Aβ-type fragments in soluble [22] and
insoluble fractions and potential loss of epitopes due to
aggregation state [39] add further difficulties in system-
atically characterising Aβ. A “panel” of antibodies to
consistently and reliably characterise Aβ-type, P3-type
and catabolic fragments in all aggregation states (mono-
mer, dimer, oligomer and fibril) is not currently possible.
Antibody reactivities and their relevance to APP
proteolytic pathways and disease
Contrary to our current understanding, the immunore-
activity profiles of commonly used antibodies do not
correspond directly to APP cleavage pathways [1, 2, 8],
summarised in Fig. 1. Immunoreactivity of antibodies
predicted to have a wide reactivity profile such as 4G8
and potentially those that react with C-terminal epitopes
representing aa40 or aa42 cannot be interpreted as giv-
ing evidence for initial α- or β- cleavages. Given that
antibodies are central to AD research and biomarker de-
velopment, it is not clear whether the antibodies cur-
rently being used to identify C-terminals do indeed
reflect Aβ40/42 or whether signals are confounded by
P3 (40/42). Additionally, very little account is taken of
the different soluble and insoluble compartments, there-
fore P3 (42), present in neuropathological deposits, may
not be present in soluble fractions and can be easily
missed if only soluble fractions are investigated. How
then do we best approach the search for reliable
biomarkers for AD?
Various morphologies of Aβ deposits have been noted
and these differ in their immunoreactivity profiles [48] –
how immunoreactivity differences associate with the dif-
ferent pathological morphologies have not been system-
atically investigated with respect to clinical dementia
status. The insoluble fragment P3 (42) may be a major
constituent of diffuse amyloid deposition and may be
relevant to disease pathways however, current
approaches have almost completely neglected any con-
tributions it might have. Cross reactivity of commonly
used antibodies between the Aβ, P3 type and catabolic
peptides confounds our current understanding and may
in part explain why clinical and neuropathological diag-
noses of AD do not correspond well in the older popula-
tion. To what extent a lack of understanding of the APP
proteolytic system as a whole derives from a misunder-
standing of antibody cross reactivities requires careful
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consideration. Neuropathological characterisation of hu-
man brain donations, essential to our understanding of
AD, requires re-evaluation.
Current immunotherapeutic approaches to target Aβ
have used passive humanised antibodies to enhance
removal of Aβ from the brain with the aim of slowing or
halting the progression of AD [49]. To date these have
had little success [49–52]. Bapineuzumab, Table 1, is
based on the monoclonal antibody 3D6 directed towards
an N-terminal epitope and Solanezumab, directed at an
epitope from the Aβ (13–28) central region [53]. Given
the uncertainty surrounding which fragments are
responsible for disease progression we highlight here, we
have to ask whether antibodies directed only at N-ter-
minal epitopes of Aβ, such as Bapineuzumab, would be
expected to change disease course. Following the failure
of both Bapineuzumab [51, 52] and Solanezumab [50] in
phase III clinical trials, refinements to the therapeutic
approach call for earlier, perhaps preventative, use of the
antibodies during the prodromal phase of AD, i.e. where
a high amyloid signal is seen on MRI but before any cog-
nitive change has occurred. However, the failure of these
trials suggests that a return to basic science and a re-
evaluation of our current understanding of the role of
Aβ in AD is also warranted. How prodromal AD relates
to those in the oldest old who have extensive pathology
after death but with intact cognitive function in life re-
mains unclear. Clarification of the physiological roles
[54–56] of the APP proteolytic system and all its frag-
ments [20, 21] in both in disease and normal ageing in
the human population is urgently required.
The implications arising from the cross reactivity of
commonly used antibodies to Aβ are profound. Cross
reactivity may be hiding more complex relationships
between AD and fragments from sequential α-, β- and
γ- cleavages that the current favoured model, the amyl-
oid cascade hypothesis, cannot account for. If P3 is in-
deed involved in disease progression then a more
flexible approach to understanding the relationships be-
tween all APP proteolytic fragments may be required
and both the presenilin hypothesis [18, 19] and the APP
matrix approach [20, 21] may be better guides to
systematically investigate this complex proteolytic system.
Conclusions
The concept of Aβ lacks clarity in terms of what we
mean by Aβ as a specific biological form and this is fur-
ther confounded by antibody cross-reactivities. The
different solubilities and aggregation states of proteolytic
fragments from γ-cleavage and their catabolism add fur-
ther complexity. These cross reactivities, often over-
looked, require urgent attention by the AD research
community. More than one antibody is required to ad-
equately characterise Aβ. We do not currently have
reliable evidence to identify any specific APP proteolytic
fragment as causal in AD progression. The correspond-
ence between Aβ immunoreactivity from any specific
antibody, neuropathology and proposed APP cleavages is
not clear and may in part explain the lack of corres-
pondence between clinical and neuropathological
diagnoses of dementia. These cross reactivities question
current therapeutic approaches to reduce Aβ via di-
rected immunotherapies, call for a detailed re-analysis of
biomarker results and call into question approaches
aimed solely at reducing β-cleavage. A detailed consider-
ation of anti-Aβ antibody cross reactivities reveals
significant uncertainty in our current understanding of
the APP proteolytic system and how this relates to dis-
ease with profound implications for current research
and therapeutic strategies.
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